1028-P: Rates of GLP1 Prescription in Patients with T2D after MI Are Poor Even among Patients Willing to Inject Insulin

Abstract

Introduction: SGLT2 inhibitors (SGLT2) and GLP1 agonists (GLP1) both reduce major adverse cardiovascular events (MACE) in patients with T2D after MI. To test whether prescription rates of these medications are associated with willingness to take injectable therapies, we examined prescription rates stratified by co-prescription of insulin in a large urban safety net teaching hospital which provided SGLT2 and GLP1 to low income patients at nominal cost. Methods: Using data from the hospital EHR for all patients with T2D and eGFR > 30 hospitalized with type 1 MI between 2018-2019, we determined rates of prescription of GLP1 and SGLT2 at one year. Results: Of the 55 patients prescribed insulin at the time of index MI admission, 9 (16%) were prescribed GLP1RA and 26 (47%) were prescribed SGLT2i at one year follow-up. In contrast, of the 68 patients not prescribed insulin at time of index MI admission, 4 (6%) were prescribed GLP1RA and 39 (57%) were prescribed SGLT2i at one year follow-up. Conclusion: Even among patients with demonstrated willingness to take injectable medications, rates of GLP1 prescription are poor overall and lower than SGLT2 prescription rates. Disclosure A.A.Dweik: None. S.Das: None. P.L.Della-penna: None. N.Sumarsono: None. C.L.Malladi: None. K.Geurink: None. C.Mathew: None. E.Moss: None. K.Peykova: None. L.Mack-boyd: None.